| Drug Name |
Ceftobiprole |
| Drug ID |
BADD_D00404 |
| Description |
Ceftobiprole is a cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus. It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development. Ceftobiprole is the first cephalosporin to demonstrate clinical efficacy in patients with infections due to methicillin-resistant staphylococci and, if approved by regulatory authorities, is expected to be a useful addition to the armamentarium of agents for the treatment of complicated skin infections and pneumonia. |
| Indications and Usage |
For the treatment of serious bacterial infections in hospitalised patients. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB04918
|
| KEGG ID |
D08885
|
| MeSH ID |
C443755
|
| PubChem ID |
135413542
|
| TTD Drug ID |
D0CI9T
|
| NDC Product Code |
Not Available |
| UNII |
5T97333YZK
|
| Synonyms |
ceftobiprole | BAL9141 | BAL 9141 |
